Pfizer’s inotuzumab ozogamicin gains FDA priority review in acute lymphoblastic leukemia

Pfizer Inc. has received a priority review designation from the U.S. Food and Drug Administration (FDA) for its innovative blood cancer drug, inotuzumab ozogamicin. This ... Read More